Delivery of A BET Protein Degrader via A CEACAM6-Targeted ADC – Highlighting Preclinical Efficacy Against Pancreatic Cancer
Time: 2:30 pm
day: Day One
Details:
- Exploring the properties of BET protein degrader as a payload and inducing the bystander effect
- Examining the pharmacological profile of our CEACAM6-EBET ADC
- Reviewing data portraying cancer-cell-killing activity and stromal modulation activity in PDX models
